Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05346354 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety Study of Ravulizumab IV in Pediatric Participants With NMOSD
A Phase 2 study of Neuromyelitis Optica Spectrum Disorder, sponsored by Alexion Pharmaceuticals.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
- 20
- Study locations
NCT05346354: Recruiting Phase 2 study of Neuromyelitis Optica Spectrum Disorder, sponsored by Alexion Pharmaceuticals.
NCT05346354 is a Phase 2 study of Neuromyelitis Optica Spectrum Disorder that is actively recruiting participants, run by Alexion Pharmaceuticals. The registered enrollment target is 12 participants, below the 65-participant average among 6 other Neuromyelitis Optica Spectrum Disorder trials with a reported enrollment target (82% lower). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05346354, a Phase 2 study of Neuromyelitis Optica Spectrum Disorder, is actively recruiting participants, sponsored by Alexion Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary purpose of this study is to evaluate the safety and efficacy of ravulizumab in pediatric participants with Neuromyelitis Optica Spectrum Disorder (NMOSD).
Conditions Studied
Interventions
- DRUG Ravulizumab
Study Locations (20)
Other
- Research Site - Le Kremlin-Bicêtre
- Research Site - Marseille
- Research Site - Montpellier
- Research Site - Bochum
- Research Site - Giessen
- Research Site - Catania
- Research Site - Chieti
- Research Site - Gallarate
- Research Site - Roma
- Research Site - Yokohama
- Research Site - Goyang-si
District of Columbia
- Research Site - Washington D.C.
Florida
- Research Site - Miami
Massachusetts
- Research Site - Boston
Missouri
- Research Site - St Louis
North Carolina
- Research Site - Durham
Pennsylvania
- Research Site - Philadelphia
Alberta
- Research Site - Edmonton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2022-06-23 |
| Est. Completion | 2029-04-02 |
| Phase | Phase 2 |
What NCT05346354 shows while recruiting
NCT05346354 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 65-participant average among 6 other Neuromyelitis Optica Spectrum Disorder trials with a reported enrollment target (82% lower).
The record links to 1 condition, with Neuromyelitis Optica Spectrum Disorder appearing as the primary indexed condition, and to 1 intervention - of which Ravulizumab is the first listed.
NCT05346354 names 20 study sites across 10 states, led by Other, District of Columbia, Florida.
Frequently Asked Questions
What is clinical trial NCT05346354 about?
NCT05346354 is a clinical study titled "Efficacy and Safety Study of Ravulizumab IV in Pediatric Participants With NMOSD". The primary purpose of this study is to evaluate the safety and efficacy of ravulizumab in pediatric participants with Neuromyelitis Optica Spectrum Disorder (NMOSD).
What is the current status of trial NCT05346354?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2022-06-23. Estimated completion is 2029-04-02.
What conditions does trial NCT05346354 study?
This clinical trial studies the following conditions: Neuromyelitis Optica Spectrum Disorder.
What interventions are being tested in trial NCT05346354?
The interventions under investigation include: Ravulizumab (DRUG).
Who is sponsoring clinical trial NCT05346354?
This trial is sponsored by Alexion Pharmaceuticals, which has 162 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05346354 being conducted?
This trial has 20 study locations across District of Columbia, Florida, Massachusetts, Missouri, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neuromyelitis Optica Spectrum Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Inebilizumab in Pediatric Subjects With Neuromyelitis Optica Spectrum Disorder
RECRUITING · Phase 2
-
Registry of Patients With AQP4+ NMOSD Treated With Alexion C5 Inhibitor Therapies
RECRUITING
-
A Study To Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, And Pharmacodynamics Of Satralizumab In Pediatric Patients With Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorder (NMOSD)
RECRUITING · Phase 3
-
Observational Safety Study in Women With Neuromyelitis Optica Spectrum Disorder (NMOSD) Exposed to UPLIZNA® During Pregnancy
RECRUITING
-
Long-term, Open-label, Safety Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD)
ACTIVE NOT RECRUITING · Phase 4
-
The Longitudinal CONQUER Study of Rare Neuroimmunologic Disorders
ACTIVE NOT RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI